The United Kingdom has one of the poorest lung cancer survival rates in Europe. In this study, to help design and evaluate a single lung cancer pathway (SCP) for Wales, existing diagnostic pathways and processes have been mapped and then modelled with a discrete event simulation. The validated model has been used to provide key performance indicators and to examine different diagnostic testing strategies. Under the current diagnostic pathways, the mean time to treatment was 72 days for surgery patients, 56 days for chemotherapy patients, and 61 days for radiotherapy patients. Our research demonstrated that by ensuring that the patient attends their first outpatient appointment within 7 days and streamlining the diagnostic tests would have t...
The diagnosis and treatment of lung cancer is challenged by complex diagnostic pathways and fragment...
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
The United Kingdom has one of the poorest lung cancer survival rates in Europe. In this study, to he...
Background: UK’s National Health Service (NHS) has one of the poorest lung cancer survival rates in ...
Cancer pathway is the name given to a patient’s journey from initial suspicion of cancer through to ...
Comparative StudyOpen Access articleOpen Access journalBACKGROUND: Lung cancer is the commonest caus...
This is an Accepted Manuscript version of 'Usame Yakutcan, Eren Demir, John R. Hurst & Paul C. Taylo...
Background This study shows how dynamic simulation modeling can be applied in the context of the na...
Published onlineJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tBACKGROUND...
Clinical pathways are an effective and effcient approach in standardising the progression of treatm...
Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patie...
Lung cancer is a major global health burden with high incidence rates but poor long-term survival. C...
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of...
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most...
The diagnosis and treatment of lung cancer is challenged by complex diagnostic pathways and fragment...
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
The United Kingdom has one of the poorest lung cancer survival rates in Europe. In this study, to he...
Background: UK’s National Health Service (NHS) has one of the poorest lung cancer survival rates in ...
Cancer pathway is the name given to a patient’s journey from initial suspicion of cancer through to ...
Comparative StudyOpen Access articleOpen Access journalBACKGROUND: Lung cancer is the commonest caus...
This is an Accepted Manuscript version of 'Usame Yakutcan, Eren Demir, John R. Hurst & Paul C. Taylo...
Background This study shows how dynamic simulation modeling can be applied in the context of the na...
Published onlineJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tBACKGROUND...
Clinical pathways are an effective and effcient approach in standardising the progression of treatm...
Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patie...
Lung cancer is a major global health burden with high incidence rates but poor long-term survival. C...
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of...
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most...
The diagnosis and treatment of lung cancer is challenged by complex diagnostic pathways and fragment...
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...